Key result
Simvastatin pretreatment significantly reduced platelet activating factor by 33.33% and thrombomodulin by 20.44% compared to untreated septic mice, improving the hypercoagulable state.
Why the study?
The study was conducted to investigate the effects of simvastatin pretreatment on platelet activation and hypercoagulable state in septic mice.
Does simvastatin pretreatment improve platelet activation and hypercoagulable state in septic mice?
Does simvastatin pretreatment improve platelet activation and hypercoagulable state in septic mice?
Simvastatin pretreatment attenuates platelet activation, hypercoagulability, oxidative stress, and inflammation in a murine model of sepsis.
Answers are grounded in this paper and cite their sources.
Simvastatin effects in septic mice do not support clinical use; hypothesis-generating for human sepsis coagulopathy trials.
OBJECTIVE: To investigate the effects of simvastatin pretreatment on platelet activation and hypercoagulable state in septic mice. METHOD: 60 Sprague-Dawley (SD) mice were divided into three groups: healthy control (group A), sepsis (group B) and simvastatin intervention (group C). The sepsis model was established by intraperitoneal injection of lipopolysaccharide in the group B: the group A was injected with normal saline, and the group C was injected with 10 μg/ml simvastatin 5 ml of simvastatin for 3 h. The changes of protein expression were detected by Western blot, blood coagulation indexes were analyzed, and the levels of serum platelet activating factor, thrombomodulin, interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-1 β (IL-1β), superoxide dismutase (SOD) and malondialdehyde (MDA) were detected by enzyme linked immunosorbent assay (ELISA) detection kit. RESULT: The levels of thrombomodulin and platelet activating factor in mice of the group B were significantly higher than those in the group A (P < 0.05). The levels of thrombomodulin and platelet activating factor in the group C of mice were significantly lower than those in the group B (P < 0.05), which were down-regulated by 20.44% and 33.33%, respectively (P < 0.05). The PT and APTT times of mice in the group B were significantly lower than those in the group A (P < 0.05). The PT and APTT times of mice in the group C were significantly higher than those in the group B (P < 0.05), which were upregulated by 29.01% and 13.08%, respectively (P < 0.05). The SOD level of mice in the group B was significantly lower than that in the group A, and the MDA level was significantly higher than that in the group A (P < 0.05). The SOD level in the group C of mice was significantly higher than that in the group B, which was upregulated by 24.77%, and the MDA level was significantly lower than that in the group B, which was down-regulated by 22.96% (P < 0.05). The levels of serum IL-6, TNF-α and IL-1β in mice of the group B were higher than those in the group A (P < 0.05). The levels of serum IL-6, TNF-α and IL-1β in the group C of mice were lower than those in the group B by 45.97%, 28.72% and 16.59%, respectively (P < 0.05). The expression levels of AMPK and UCP2 proteins in the group B of mice were lower than those in the group A (P < 0.05). The expression levels of AMPK and UCP2 proteins in the group C of mice were higher than those in the group B, which were upregulated by 55.00% and 28.81%, respectively (P < 0.05). CONCLUSION: Simvastatin pretreatment can improve platelet activation and hypercoagulable state in septic mice.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied Sepsis (n=60). Simvastatin vs. Sepsis (LPS only) and healthy control (normal saline) was evaluated on Platelet activating factor (pg/mL) (33.33% reduction, p=<0.05). Simvastatin pretreatment significantly reduced platelet activating factor by 33.33% and thrombomodulin by 20.44% compared to untreated septic mice, improving the hypercoagulable state.
Synapse has enriched 10 related papers. Consider them for comparative context: